Pharmic Activation of PKG2 Alleviates Diabetes-Induced Osteoblast Dysfunction by Suppressing PLCβ1-Ca²⁺-Mediated Endoplasmic Reticulum Stress

Figure 4

Cinaciguat alleviates T2DM-induced osteogenesis injury by upregulating PKG2. (a) The protein level of PKG2 was detected by western blot after 7 days of adding cinaciguat. (b) Immunofluorescent staining was performed to examine the expression of PKG2 after 3 days of adding cinaciguat. . (c) Quantitative analysis of mean fluorescence intensity of PKG2. (d) The knockdown efficiency of PKG2 was verified by western blot. (e) EDU staining was performed to test the osteoblasts undergoing DNA replication. Red, EDU positive nucleus. Blue, all nucleus. . (f) The quantification analysis of EDU-positive cells. (g) Flow cytometer analysis was conducted to detect cells apoptosis. (h) The quantification analysis of apoptosis rate. (i) Cytoskeleton (red) was stained by rhodamine-phalloidin, and nucleus (blue) was stained by DAPI. . (j) ALP activity assay after 7 days induction. (k) ALP staining after 7 days induction. (l) The protein levels of COL1, ALP, and RUNX2 were detected by western blot after 7 days induction. Data were presented as from at least three independent experiments. : . Cina: cinaciguat; RP: rhodamine-phalloidin.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)